Delphinol® displays marked antioxidant powers in ORAC testing (> 30000 µM TE/g), with significantly lowered oxidised LDL by 40% and F2-isoprostane by 28%, in placebo controlled clinical trial. Delphinol® inhibits intestinal glucose transporter SGLT (patented) and hence extends to lower blood sugar absorption to include consumed refined sugars such as glucose. Clinical trials point to high efficacy and excellent tolerability.
Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.